SARASOTA RETINA INSTITUTE STUDIES
The Sarasota Retina Institute researches, diagnoses and treats diseases of the Retina, Optic Nerve and Orbit. Sarasota Retina Institute has been internationally recognized for treating complex eye problems such as Macular Degeneration, Retinal Detachments, Diabetic and Thyroid-Related Eye Diseases, Strabismus, Optic Nerve Diseases, Ocular Trauma and infections.
The Institute is currently participating in the following national clinical trials to enhance knowledge, evaluate and treat people with the latest drugs and devises to improve their vision problems.
BLOOD DRAW AND TEAR COLLECTION STUDIES:
BioIVT SeraTrials
Blood draws and tear collections for a number of different diagnoses and for healthy donors.
DIABETIC RETINOPATHY:
DRCR-AF
A study to evaluate the pill Fenofibrate to prevent diabetic retinopathy worsening in diabetics 18-80 years of age.
LIPID METABOLISM:
DRCR-AFA
A study of diabetic retinopathy and changes in lipid metabolism.
EPIRETINAL MEMBRANES:
DRCR-AM
A study comparing immediate versus deferred surgery for symptomatic epiretinal membranes.
HOME OCT:
DRCR-AO
A study of home OCT-guided treatment versus treat and extend for the management of neovascular AMD.
IMPLANTABLE MINIATURE TELESCOPE:
SING IMT Smaller-Incision New Generation Implantable Miniature Telescope
Implantable Miniature Telescope designed to improve visual acuity and quality of life for patients with late-stage age-related macular degeneration (AMD).
THYROID EYE DISEASE (TED):
Thrive /MAD
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001 in
subjects with thyroid eye disease (TED)
Thrive-2
A study of VRDN-001 in participants with chronic thyroid eye disease (TED).
Thrive OLE
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies
Strive
A study of VRDN-001 in participants with thyroid eye disease (TED) of any duration.
Reveal-1
A Phase 3 study of VRDN-003 in participants with active thyroid eye disease (TED) of LESS than 15 months duration.
Reveal-2
A Phase 3 study of VRDN-003 in participants with chronic thyroid eye disease (TED) of MORE than 15 months duration.
UplighTED
A Phase 3 study to evaluate Efgartigimod PH20 SC administered by prefilled syringe in adult participants with Thyroid Eye Disease (TED) of less than 12 months duration.
Amgen 20230302
A Phase 1/2 study of AMG 732 in subjects with moderate-to-severe active thyroid eye disease (TED) symptoms of LESS than 15 months duration.
Sarasota Retina Institute also collaborates with Florida Cancer Specialists and Roskamp Institute as ophthalmologists for their clinical trials.
If you are interested in finding out if you might be a candidate for one of our studies, please contact us at (941) 921-5335.